BCRB 2018

Challenge - High quality translational research

• New targeted therapies require different clinical trials

– New therapies may be highly TUMOR or PATIENT specific – need biomarkers

– Single attributes (eg hypoxia) or single molecules (EGFR) are targets

– Benefit limited to specific, perhaps small patient populations